Intangible Assets

AIMD does not appear to have durable brand, patent, or regulatory assets that materially protect pricing power versus larger medtech peers, so customer willingness to pay is unlikely to be structurally insulated.

The provided TTM ROIC of -80.5% and ROCE of -419.1% indicate the company is not converting any putative IP into economic returns, which is weaker than established peers with proven monetization.

No evidence in the supplied data suggests a proprietary clinical standard or exclusive indication that would force peer-dependent adoption, so any intangible advantage looks limited and contestable.

Compared with scaled medtech peers that typically defend margins through entrenched brands, broad surgeon familiarity, or protected product portfolios, AIMD’s intangible moat appears materially less durable.

Switching Costs

AIMD does not show evidence of high switching costs because the available metrics do not indicate embedded workflows, long-term contracts, or installed-base dependence that would lock in customers versus peers.

The very low asset turnover and negative returns suggest the business is not yet operating at a level where customer retention is being monetized through repeat usage or service attachment.

In medtech, switching costs are strongest when clinicians, hospitals, and procurement teams face retraining, validation, or procedure disruption, but no such structural lock-in is evidenced here.

Relative to peers with broad installed bases and recurring consumables or service revenue, AIMD appears easier to substitute, which limits long-run pricing power and retention.

Network Effects

AIMD shows no visible network effect because the supplied data do not indicate a platform, data flywheel, or user-to-user interaction that would make the product more valuable as adoption rises.

Medical device businesses can sometimes benefit from procedure standardization, but that is not the same as a true network effect and is not evidenced here.

The absence of profitability and scale signals suggests AIMD is not yet accumulating the ecosystem density that would create peer-reinforcing demand.

Compared with platform-like healthcare IT or dominant procedure ecosystems, AIMD’s network effects appear negligible and do not support durable moat strength.

Cost Advantage

AIMD’s negative ROIC and ROCE imply it is not operating with a cost structure that converts into superior unit economics versus peers.

The extremely low asset turnover suggests weak asset productivity, which is inconsistent with a structural manufacturing, sourcing, or distribution advantage.

No evidence is provided of scale purchasing, proprietary manufacturing yield, or lower service costs that would let AIMD underprice peers while preserving margins.

Relative to larger medtech competitors that can spread R&D, regulatory, and commercial costs across broader revenue bases, AIMD appears disadvantaged rather than advantaged on cost.

Efficient Scale

AIMD does not appear to operate in a niche where one or two firms can efficiently serve the market and deter entry, because the supplied data do not show dominant share or capacity constraints.

The negative profitability metrics suggest the company has not yet reached a scale position that would make incremental competition uneconomic for peers.

Efficient scale is strongest when market size is limited and fixed costs are high, but no evidence here shows AIMD controlling such a protected niche better than peers.

Compared with established medtech leaders that can justify large commercial footprints and regulatory overhead, AIMD’s scale position does not look sufficient to create durable entry barriers.

Overall Score

AIMD’s moat appears weak versus peers because the available evidence shows no durable intangible assets, switching costs, network effects, cost advantage, or efficient-scale protection, and the deeply negative ROIC/ROCE reinforce that any competitive position is not yet translating into durable economic returns.